Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment

Digestive Diseases

Volumn 35, Issue 3, 2017, Pages 275-281

  Perugorria, Maria J ^a,b,c   Labiano, Ibone ^a,b   Esparza Baquer, Aitor ^a   Marzioni, Marco ^e   Marin, Jose J G ^b,d   Bujanda, Luis ^a,b   Banales, Jesús M ^a,b,c  

^a HOSPITAL DONOSTIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Bile acids; Polycystic liver disease; Therapy; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; ANGIOPEPTIN; BILE ACID; CYCLIC AMP; GAMMA GLUTAMYLTRANSFERASE; GLYCOCHENODEOXYCHOLIC ACID; GLYCODEOXYCHOLIC ACID; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN RECEPTOR; TAUROCHENODEOXYCHOLIC ACID; TAURODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID;

ABNORMAL FECES; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; CALCIUM CELL LEVEL; CELL GROWTH; CELL PROLIFERATION; CELLULAR SECRETION; CHOLANGIOCYTE; CHOLESTASIS; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE COURSE; HUMAN; KIDNEY POLYCYSTIC DISEASE; LIVER POLYCYSTIC DISEASE; LIVER PROTECTION; LIVER WEIGHT; META ANALYSIS (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; ANIMAL; CALCIUM SIGNALING; CYSTS; DISEASE MODEL; LIVER DISEASES; METABOLISM; PATHOLOGY;

ANIMALS; BILE ACIDS AND SALTS; CALCIUM SIGNALING; CYCLIC AMP; CYSTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; LIVER DISEASES;

EID: 85014682499     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000450989     Document Type: Article

References (45)

1. Gevers TJ, Drenth JP: Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol 2013; 10: 101-108.
2. Perugorria MJ, Masyuk TV, Marin JJ, Marzioni M, Bujanda L, LaRusso NF, Banales JM: Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol 2014; 11: 750-761.
3. Banales JM, Munoz-Garrido P, Bujanda L: Somatic second-hit mutations leads to polycystic liver diseases. World J Gastroenterol 2013; 19: 141-143.
4. Drenth JP, te Morsche RH, Smink R, Bonifacino JS, Jansen JB: Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet 2003; 33: 345-347.
5. Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, Cai Y, Kamath PS, King BF, Azurmendi PJ, Tahvanainen P, Kaariainen H, Hockerstedt K, Devuyst O, Pirson Y, Martin RS, Lifton RP, Tahvanainen E, Torres VE, Somlo S: Mutations in sec63 cause autosomal dominant polycystic liver disease. Nat Genet 2004; 36: 575-577.
6. Cnossen WR, te Morsche RH, Hoischen A, Gilissen C, Chrispijn M, Venselaar H, Mehdi S, Bergmann C, Veltman JA, Drenth JP: Whole-exome sequencing reveals LRP5 mutations and canonical wnt signaling associated with hepatic cystogenesis. Proc Natl Acad Sci U S A 2014; 111: 5343-5348.
7. Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Banales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrezet MP, Ferec C, Le Meur Y, Torres VE; Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC: Mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomaldominant polycystic kidney and liver disease. Am J Hum Genet 2016; 98: 1193-1207.
8. Fedeles SV, Tian X, Gallagher AR, Mitobe M, Nishio S, Lee SH, Cai Y, Geng L, Crews CM, Somlo S: A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet 2011; 43: 639-647.
9. Wijnands TF, Neijenhuis MK, Kievit W, Nevens F, Hogan MC, Torres VE, Gevers TJ, Drenth JP: Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int 2014; 34: 1578-1583.
10. Wills ES, Roepman R, Drenth JP: Polycystic liver disease: ductal plate malformation and the primary cilium. Trends Mol Med 2014; 20: 261-270.
11. Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF: The cAMP effectors epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009; 49: 160-174.
12. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Masyuk AI, Gradilone SA, Gajdos GB, Chandok N, Bakeberg JL, Ward CJ, Ritman EL, Kiyokawa H, LaRusso NF: Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology 2012; 142: 622-633.e4.
13. Banales JM, Masyuk TV, Bogert PS, Huang BQ, Gradilone SA, Lee SO, Stroope AJ, Masyuk AI, Medina JF, LaRusso NF: Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008; 173: 1637-1646.
14. Masyuk TV, Lee SO, Radtke BN, Stroope AJ, Huang B, Banales JM, Masyuk AI, Splinter PL, Gradilone SA, Gajdos GB, LaRusso NF: Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. Am J Pathol 2014; 184: 110-121.
15. Urribarri AD, Munoz-Garrido P, Perugorria MJ, Erice O, Merino-Azpitarte M, Arbelaiz A, Lozano E, Hijona E, Jimenez-Aguero R, Fernandez-Barrena MG, Jimeno JP, Marzioni M, Marin JJ, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Banales JM: Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut 2014; 63: 1658-1667.
16. Fabris L, Cadamuro M, Fiorotto R, Roskams T, Spirli C, Melero S, Sonzogni A, Joplin RE, Okolicsanyi L, Strazzabosco M: Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 2006; 43: 1001-1012.
17. Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, LaRusso N: Micro-RNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008; 118: 3714-3724.
18. Masyuk TV, Masyuk AI, Torres VE, Harris PC, LaRusso NF: Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′ ,5′-cyclic monophosphate. Gastroenterology 2007; 132: 1104-1116.
19. Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Saez E, Uriz M, Sarvide S, Portu A, Concepcion AR, Romero MR, Monte MJ, Santos-Laso A, Hijona E, Jimenez-Aguero R, Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JP, Banales JM: Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol 2015; 63: 952-961.
20. Marin JJ, Macias RI, Briz O, Banales JM, Monte MJ: Bile acids in physiology, pathology and pharmacology. Curr Drug Metab 2015; 17: 4-29.
21. Puglielli L, Amigo L, Arrese M, Nunez L, Rigotti A, Garrido J, Gonzalez S, Mingrone G, Greco AV, Accatino L, et al: Protective role of biliary cholesterol and phospholipid lamellae against bile acid-induced cell damage. Gastroenterology 1994; 107: 244-254.
22. Masyuk TV, Huang BQ, Ward CJ, Masyuk AI, Yuan D, Splinter PL, Punyashthiti R, Ritman EL, Torres VE, Harris PC, LaRusso NF: Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology 2003; 125: 1303-1310.
23. Masyuk AI, Huang BQ, Radtke BN, Gajdos GB, Splinter PL, Masyuk TV, Gradilone SA, LaRusso NF: Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am J Physiol Gastrointest Liver Physiol 2013; 304:G1013-G1024.
24. LaRusso NF, Masyuk TV, Hogan MC: Polycystic liver disease: the benefits of targeting cAMP. Clin Gastroenterol Hepatol 2016; 14: 1031-1034.
25. Spirli C, Locatelli L, Fiorotto R, Morell CM, Fabris L, Pozzan T, Strazzabosco M: Altered store operated calcium entry increases cyclic 3′ ,5′-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes. Hepatology 2012; 55: 856-868.
26. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, LaRusso NF: Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 2013; 58: 409-421.
27. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP: Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-1668.e1-e2.
28. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P: Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5: 783-789.
29. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE: Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-1061.
30. Temmerman F, Gevers T, Ho TA, Vanslembrouck R, Coudyzer W, van Pelt J, Bammens B, Pirson Y, Drenth JP, Nevens F: Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data. Aliment Pharmacol Ther 2013; 38: 397-406.
31. Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, Hoffmann AL, Dekker HM, de Man RA, van Keimpema L, Drenth JP: The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012; 35: 266-274.
32. Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, LaRusso NF, Torres VE: Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27: 3532-3539.
33. Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, Ihrke A, Severson AL, Irazabal MV, Glockner J, LaRusso NF, Torres VE: Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease. Mayo Clin Proc 2015; 90: 1030-1037.
34. Temmerman F, Ho TA, Vanslembrouck R, Coudyzer W, Billen J, Dobbels F, van Pelt J, Bammens B, Pirson Y, Nevens F: Lanreotide reduces liver volume, but might not improve muscle wasting or weight loss, in patients with symptomatic polycystic liver disease. Clin Gastroenterol Hepatol 2015; 13: 2353-2359.e1.
35. Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, Nevens F, Drenth JP: Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology 2013; 145: 357-365.e1-e2.
36. Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P; ALADIN Study Group: Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease. Clin Gastroenterol Hepatol 2016; 14: 1022-1030.e4.
37. Gradilone SA, Masyuk TV, Huang BQ, Banales JM, Lehmann GL, Radtke BN, Stroope A, Masyuk AI, Splinter PL, LaRusso NF: Activation of trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology 2010; 139: 304-314.e2.
38. Paumgartner G, Beuers U: Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited. Hepatology 2002; 36: 525-531.
39. Poupon R: Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36(suppl 1):S3-S12.
40. Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sanchez Pozzi EJ: Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 2011; 121: 523-544.
41. Beuers U, Trauner M, Jansen P, Poupon R: New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62(1 suppl):S25-S37.
42. Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, Beuers U: A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012; 55: 173-183.
43. Alpini G, Baiocchi L, Glaser S, Ueno Y, Marzioni M, Francis H, Phinizy JL, Angelico M, Lesage G: Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology 2002; 35: 1041-1052.
44. D'Agnolo HM, Kievit W, Takkenberg RB, Riano I, Bujanda L, Neijenhuis MK, Brunenberg EJ, Beuers U, Banales JM, Drenth JP: Ursodeoxycholic acid in advanced polycystic liver disease: a phase 2 multicenter randomized controlled trial. J Hepatol 2016; 65: 601-607.
45. Iijima T, Hoshino J, Suwabe T, Sumida K, Mise K, Kawada M, Imafuku A, Hayami N, Hiramatsu R, Hasegawa E, Sawa N, Takaichi K, Ubara Y: Ursodeoxycholic acid for treatment of enlarged polycystic liver. Ther Apher Dial 2016; 20: 73-78.